BACKGROUND: It has been suggested that intensive lipid-lowering therapy using statins significantly decreases atheromatous plaque volume. The effect of rosuvastatin on plaque volume in patients with stable coronary artery disease (CAD), including those receiving prior lipid-lowering therapy, was examined in the present study. METHODS AND RESULTS: A 76-week open-label trial was performed at 37 centers in Japan. Eligible patients began treatment withrosuvastatin 2.5 mg/day, which could be increased at 4-week intervals to <or=20 mg/day. A total of 214 patients underwent intravascular ultrasound (IVUS) at baseline; 126 patients had analyzable IVUS images at the end of the study. The change in the serum low-density lipoprotein-cholesterol level from baseline to end of follow-up was -38.6 +/-16.9%, whereas that of high-density lipoprotein-cholesterol was +19.8 +/-22.9% (both P<0.0001). Percent change of plaque volume, the primary endpoint, was -5.1 +/-14.1% (P<0.0001). CONCLUSIONS:Rosuvastatin exerted significant regression of coronary plaque volume in Japanese patients with stable CAD, including those who had previously used other lipid-lowering drugs. Rosuvastatin might be useful in the setting of secondary prevention in patients with stable CAD.
RCT Entities:
BACKGROUND: It has been suggested that intensive lipid-lowering therapy using statins significantly decreases atheromatous plaque volume. The effect of rosuvastatin on plaque volume in patients with stable coronary artery disease (CAD), including those receiving prior lipid-lowering therapy, was examined in the present study. METHODS AND RESULTS: A 76-week open-label trial was performed at 37 centers in Japan. Eligible patients began treatment with rosuvastatin 2.5 mg/day, which could be increased at 4-week intervals to <or=20 mg/day. A total of 214 patients underwent intravascular ultrasound (IVUS) at baseline; 126 patients had analyzable IVUS images at the end of the study. The change in the serum low-density lipoprotein-cholesterol level from baseline to end of follow-up was -38.6 +/-16.9%, whereas that of high-density lipoprotein-cholesterol was +19.8 +/-22.9% (both P<0.0001). Percent change of plaque volume, the primary endpoint, was -5.1 +/-14.1% (P<0.0001). CONCLUSIONS:Rosuvastatin exerted significant regression of coronary plaque volume in Japanese patients with stable CAD, including those who had previously used other lipid-lowering drugs. Rosuvastatin might be useful in the setting of secondary prevention in patients with stable CAD.
Authors: Rine Nakanishi; Anas Alani; Suguru Matsumoto; Dong Li; Michael Fahmy; Jeby Abraham; Christopher Dailing; Alexander Broersen; Pieter H Kitslaar; Khurram Nasir; James K Min; Matthew J Budoff Journal: Tex Heart Inst J Date: 2018-04-07